Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections

Eur Respir J. 2017 Mar 22;49(3):1601969. doi: 10.1183/13993003.01969-2016. Print 2017 Mar.

Authors

Silvan Vesenbeckh¹, Nicolas Schönfeld², David Krieger², Gudrun Bettermann³, Torsten Thomas Bauer^{2

4}, Holger Rüssmann³, Harald Mauch³

Affiliations

¹ Klinik für Pneumologie, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany silvan.vesenbeckh@helios-kliniken.de.
² Klinik für Pneumologie, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany.
³ Institut für Mikrobiologie, Immunologie und Laboratoriumsmedizin, HELIOS Klinikum Emil von Behring, Berlin, Germany.
⁴ Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK), Berlin, Germany.

PMID: 28331039
DOI: 10.1183/13993003.01969-2016

No abstract available

Publication types

Letter

MeSH terms

Antitubercular Agents / therapeutic use*
Diarylquinolines / therapeutic use*
Humans
Mycobacterium avium Complex / isolation & purification*
Mycobacterium avium-intracellulare Infection / drug therapy*

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline